Mitchell Davis

Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection

Eric Lawitz, Alessandra Mangia, David Wyles et al. · New England Journal of Medicine · 2013 · 1.8K citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2009 · 1.2K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Paul Y. Kwo, Eric Lawitz, Jonathan McCone et al. · The Lancet · 2010 · 704 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

Kris V. Kowdley, Eric Lawitz, Israel Crespo et al. · The Lancet · 2013 · 296 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15